Peking University Third Hospital Drug Clinical Trial Institution Participates in the 2026 CMAC Conference

Author: Guo Zijing

https://www.puh3.net.cn/info/1971/171601.htm

From March 18 to 20, the 2026 CMAC Conference and Exhibition was held in Suzhou. The Drug Clinical Trial Institution of Peking University Third Hospital was invited to participate and set up a booth, comprehensively showcasing its cutting-edge achievements and overall capabilities.

The Drug Clinical Trial Institution of Peking University Third Hospital organized two thematic forums: Early Clinical Research Strategies and Scientific Regulation, and Quantitative Pharmacology-AI-Assisted Innovative Drug Discovery and Translational Research. Professor Li Haiyan, Director of the Drug Clinical Trial Institution, attended the themed conference on drug regulation and innovation and delivered a presentation titled Practice of ICH E6(R3) in Innovative Drug Research and Development. Chief Physician Wang Fangfang, head of the Phase I research ward; Xu Yan, head of institutional operations; Niu Xiaoye, head of operations for the Phase I research ward; Liu Zhiping, head nurse of the Phase I research ward; Associate Researcher Cui Cheng; Associate Researcher Yang Zhenzhen; and Assistant Researcher Liang Hao each delivered thematic presentations. Liu Dongyang, Deputy Director of the institution, and others participated in roundtable discussions and chaired sessions.